Portage biotech announce re-launch of adenosine subsidiary as independently managed company; appointment of peter molloy to lead new company

Westport, conn., jan. 06, 2025 (globe newswire) -- portage biotech, inc. (“portage” or the “company”) (nasdaq: prtg), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced the re-launch of its wholly-owned subsidiary as an independently managed company focused on developing best-in-class adenosine receptor antagonists.
ATON Ratings Summary
ATON Quant Ranking